Is iron sucrose injection is safe in pregnancy or not?
Reading File
Finding Sources
Searching PubMed
"iron sucrose" AND pregnancy AND safety
Reading File
Reading File
Reading Article
Reading File
Reading File
I now have comprehensive information from authoritative textbook sources and the latest Cochrane review. Here is a full answer:
Iron Sucrose Injection in Pregnancy: Safety Profile
Pregnancy Category & Classification
Iron sucrose (brand name Venofer) carries FDA Pregnancy Category B - meaning animal reproduction studies have not demonstrated fetal risk, and there are no adequate, well-controlled studies in pregnant women. This is a more favorable rating than iron dextran, which is Category C.
- The Harriet Lane Handbook (23rd ed.): "Pregnancy category is 'B' for ferric gluconate and iron sucrose and 'C' for iron dextran."
When Is It Used?
Parenteral iron - with iron sucrose being the most commonly used formulation - is appropriate when:
- Oral iron has failed or is not tolerated
- Severe iron deficiency anemia (IDA) requires rapid correction
- Malabsorption syndromes prevent oral absorption
- The patient is significantly anemic and refuses oral iron
Iron sucrose is preservative-free (no benzyl alcohol, unlike ferric gluconate), which makes it preferable in pregnancy. Ferric gluconate contains benzyl alcohol, which carries potential fetal risk.
Trimester Considerations
- 1st trimester: Generally avoided due to theoretical concerns about fetal organogenesis. No strong evidence of harm, but most guidelines recommend deferring until the 2nd trimester unless the clinical situation is urgent.
- 2nd and 3rd trimesters: Considered safe and effective. This is when IV iron sucrose is most commonly administered in obstetric practice.
Efficacy Evidence
Creasy & Resnik's Maternal-Fetal Medicine summarizes:
A meta-analysis of 11 RCTs (~600 patients in each arm) found that iron sucrose was used in 9 of the 11 trials. After 4 weeks of treatment, hemoglobin was significantly higher in IV iron-treated patients, the target Hb of 11-12 g/dL was achieved more often, there were no hypersensitivity reactions, and adverse events were significantly lower compared to oral iron groups.
Dosing Formula
A standard dosing strategy:
Dose (mg) = Patient weight (kg) × (Target Hb - Actual Hb in g/dL) × 0.24 + 500 mg
- Target Hb is generally 11-12 g/dL
- Maximum single-day infusion dose: 300-500 mg, diluted in NS and given over at least 15-30 minutes
Safety Profile and Adverse Effects
| Effect | Notes |
|---|---|
| Hypersensitivity / anaphylaxis | Rare; no test dose required (unlike low-MW iron dextran) |
| Urticaria, pruritus, dyspnea | Uncommon; infusion rate-related |
| Hypotension | Can occur with rapid infusion |
| Headache, arthralgias, chills | Mild, transient |
| Neonatal/fetal harm | No established harm in 2nd/3rd trimester |
Iron sucrose is preservative-free and does not require a test dose, making it one of the safest IV iron options in pregnancy.
2024 Cochrane Review (PMID: 39651609)
The most recent Cochrane systematic review (Nicholson et al., 2024 - 13 RCTs, 3,939 participants) found:
- IV iron (mostly iron sucrose in included trials) likely slightly increases Hb at 3-6 weeks vs. oral iron (MD +0.49 g/dL; moderate-certainty evidence)
- Reduces anemia at 3-6 weeks (RR 0.81)
- Higher Hb levels near delivery and postpartum
- Overall safety profile was acceptable, with no signal of major maternal or fetal harm
Summary
Yes, iron sucrose is considered safe in pregnancy, particularly from the 2nd trimester onward. It is the preferred IV iron preparation in obstetrics due to its:
- FDA Pregnancy Category B rating
- Preservative-free formulation
- No requirement for a test dose
- Favorable safety profile in multiple RCTs and meta-analyses
- Superior efficacy compared to oral iron for raising hemoglobin
It should be used under medical supervision with monitoring of vital signs during infusion. Avoid during the 1st trimester unless clinically essential.
Sources: Creasy & Resnik's Maternal-Fetal Medicine; The Harriet Lane Handbook (23rd ed.); Cochrane Database Syst Rev 2024 (PMID: 39651609); Lancet Haematol 2021 (PMID: 34171281)
This is a shared conversation. Sign in to Orris to start your own chat.